ABVC Biopharma Files 8-K/A Amendment on Listing Rule Compliance
Ticker: ABVC · Form: 8-K/A · Filed: Jan 13, 2025 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K/A |
| Filed Date | Jan 13, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-rules, amendment, disclosure
TL;DR
ABVC Bio filing amendment on listing rules - could be trouble.
AI Summary
ABVC Biopharma, Inc. filed an amendment (8-K/A) on January 13, 2025, to a previous report dated July 12, 2024. This amendment concerns a notice of delisting or failure to meet continued listing rules, Regulation FD disclosure, and financial statements. The filing date for the earliest event reported is January 10, 2025.
Why It Matters
This filing indicates potential issues with ABVC Biopharma's continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: medium — Filings related to delisting or failure to meet listing standards suggest potential financial or operational difficulties that could impact the company's stock.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- 0001173313 (company) — Central Index Key
- January 13, 2025 (date) — Filing Date
- July 12, 2024 (date) — Earliest Event Reported Date
- January 10, 2025 (date) — Date as of Change
FAQ
What specific listing rule or standard did ABVC Biopharma, Inc. fail to satisfy, as indicated by the 8-K/A filing?
The filing is an amendment to a Form 8-K and mentions 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard' as an item, but the specific rule or standard is not detailed in the provided text.
What is the significance of the 'Date as of Change' being January 10, 2025, for this filing dated January 13, 2025?
The 'Date as of Change' of January 10, 2025, indicates the date on which the information reported in the filing became effective or was updated, preceding the actual filing date of January 13, 2025.
What was the original filing date that this 8-K/A is amending?
The 8-K/A is an amendment to a report where the earliest event reported was on July 12, 2024.
What are the other items included in this 8-K/A filing besides the notice of potential delisting?
The filing also includes information related to Regulation FD Disclosure and Financial Statements and Exhibits.
What is the state of incorporation for ABVC Biopharma, Inc. and its fiscal year end?
ABVC Biopharma, Inc. is incorporated in Nevada and its fiscal year ends on December 31.
Filing Stats: 674 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-10 18:56:29
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
- $1.00 — et the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listin
Filing Documents
- ea0227316-8ka1_abvcbio.htm (8-K/A) — 27KB
- ea022731601ex99-1_abvcbio.htm (EX-99.1) — 10KB
- ex99-1_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-002769.txt ( ) — 218KB
- abvc-20240712.xsd (EX-101.SCH) — 3KB
- abvc-20240712_lab.xml (EX-101.LAB) — 33KB
- abvc-20240712_pre.xml (EX-101.PRE) — 22KB
- ea0227316-8ka1_abvcbio_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 9, 2025, ABVC BioPharma, Inc. (the "Company") received a notification from Nasdaq granting the Company an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement of $1.00 per share, as outlined in Nasdaq Listing Rule 5550(a)(2) (the "Rule"). On July 12, 2024, the Company disclosed that Nasdaq had informed it that its stock had failed to maintain the minimum bid price over the preceding 30 business days. At that time, the Company was given until January 6, 2025, to regain compliance. The current extension was granted based on the Company's adherence to other listing requirements and assurance that it would take necessary steps to meet the compliance. To satisfy the Rule, the Company's common stock must achieve a closing bid price of at least $1.00 for a minimum of ten consecutive trading days within this extension period; if successful, Nasdaq will confirm compliance with the Rule and close this matter. If compliance is not achieved by the new deadline, Nasdaq may initiate delisting procedures, which the Company would have the right to appeal. This extension has no immediate impact on the Company's listing, and its stock will continue to trade on the Nasdaq Capital Market under the ticker symbol "ABVC." The Company is actively monitoring its stock price and evaluating potential measures to ensure compliance within the given timeframe, including executing a reverse stock split.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 13, 2025, the Company plans to issue a press releases announcing the additional 180-day extension to regain compliance with the minimum bid price requirement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01 Exhibits
Item 9.01 Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File, formatted in Inline XBRL SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. January 10, 2025 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer